Asundexian - Bayer
Alternative Names: BAY-2433334Latest Information Update: 14 Dec 2023
At a glance
- Originator Bayer
- Class Amides; Anticoagulants; Antithrombotics; Chlorobenzenes; Ethers; Fluorobenzenes; Pyridines; Small molecules; Triazoles; Vascular disorder therapies
- Mechanism of Action Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Stroke; Thromboembolism
Most Recent Events
- 13 Dec 2023 Bayer terminates phase III OCEANIC-AF trial due to an inferior efficacy in Stroke (Prevention) in China, Australia, Argentina, Austria, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, New Zealand, South Korea, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, UK (PO)
- 13 Dec 2023 Bayer terminates phase III OCEANIC-AF trial due to an inferior efficacy in Thromboembolism (Prevention) (with atrial fibrillation) in India, Italy, Kazakhstan, Portugal, Turkey, China, Australia, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, UK (PO)
- 10 Nov 2023 Phase-III clinical trials in Thromboembolism (In the elderly, Prevention) in USA (PO) before June 2023